Skip to main content

Table 1 The OR and 95% CI of variants associating with gout/hyperuricemia in those carrying rs2231142 (ABCG2) wild type (GG)

From: Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study

No.

SNP

Gout/hyperuricemia

Normal

OR (95% CI)

p-values

Relationship between gout and normal subjects ( n =13,088)

1

rs3733589 (SLC2A9; chr4:9985700)

GG

754 (42.38)

4019 (35.62)

  

GA

820 (46.09)

5393 (47.80)

0.81 (0.73-0.90)

1.16e-04

AA

205 (11.52)

1870 (16.58)

0.58 (0.50-0.69)

8.90e-11

2

rs3775948 (SLC2A9; Chr4:9993558)

GG

719 (40.39)

3721 (33.07)

  

GC

835 (46.91)

5386 (47.87)

0.80 (0.72-0.89)

6.40e-05

CC

226 (12.70)

2144 (19.06)

0.55 (0.47-0.64)

3.74e-14

3

rs1014290 (SLC2A9; Chr4:10000237)

GG

736 (41.30)

3900 (34.53)

  

GA

838 (47.03)

5376 (47.60)

0.83 (0.74-0.92)

4.70e-04

AA

208 (11.67)

2019 (17.88)

0.55 (0.46-0.64)

1.85e-13

4

rs17407555 (ZNF518B; chr4:10273370)

AA

1155 (64.85)

8146 (72.11)

  

AG

563 (31.61)

2896 (25.64)

1.37 (1.23-1.53)

1.38e-08

GG

63 (3.54)

255 (2.26)

1.74 (1.31-2.31)

9.67e-05

5

rs2725231 (PKD2; chr4:88013803)

AA

694 (39.01)

5138 (45.52)

  

AG

835 (46.94)

5011 (44.39)

1.23 (1.11-1.37)

1.34e-04

GG

250 (14.05)

1139 (10.09)

1.63 (1.39-1.90)

1.37e-09

6

rs3109823 (ABCG2; chr4:88143450)

CC

942 (52.95)

5154 (45.71)

  

CT

711 (39.97)

4954 (43.93)

0.79 (0.71-0.87)

6.06e-06

TT

126 (7.08)

1168 (10.36)

0.59 (0.48-0.72)

1.09e-07

7

rs2622604 (ABCG2; chr4:88157772)

TT

1017 (57.10

5388 (47.72)

  

TC

654 (36.72)

4875 (43.18)

0.71 (0.64-0.79)

2.06e-10

CC

110 (6.18)

1027 (9.10)

0.57 (0.46-0.70)

6.43e-08

8

rs6532055 (ABCG2; chr4:88197235)

TT

869 (48.93)

4621 (41.00)

  

TC

729 (41.05)

5202 (46.15)

0.75 (0.67-0.83)

5.20e-08

CC

178 (10.02)

1448 (12.85)

0.65 (0.55-0.78)

1.06e-06

9

rs72554040 (ABCG2; chr4:88231172)

GG

544 (30.60)

2644 (23.40)

  

GA

824 (46.34)

5581 (49.40)

0.72 (0.64-0.81)

3.03e-08

AA

410 (23.06)

3072 (27.19)

0.65 (0.56-0.74)

7.15e-10

10

rs671 (ALDH2; chr12:111803962)

GG

1031 (57.89)

5656 (50.06)

  

GA

624 (35.04)

4695 (41.55)

0.73 (0.66-0.81)

5.89e-09

AA

126 (7.07)

948 (8.39)

0.73 (0.60-0.89)

1.64e-03

11

rs78069066 (MAPKAPK5; chr12:111900120)

GG

1020 (57.43)

5601 (49.68)

  

GA

630 (35.47)

4706 (41.74)

0.74 (0.66-0.82)

1.41e-08

AA

126 (7.09)

967 (8.58)

0.72 (0.59-0.87)

8.40e-04

12

rs77768175 (HECTD4; chr12:112298314)

0AA

1029 (57.87)

5641 (50.05)

  

1AG

625 (35.15)

4688 (41.60)

0.73 (0.66-0.81)

7.66e-09

2GG

124 (6.97)

941 (8.35)

0.72 (0.59-0.88)

1.28e-03

Relationship between hyperuricemia and normal subjects ( n =16,395)

1

rs10805346 (SLC2A9; chr4:9918723)

TT

2302 (45.28)

5677 (50.28)

  

TC

2251 (44.28)

4626 (40.97)

1.20 (1.12-1.29)

3.11e-07

CC

531 (10.44)

988 (8.75)

1.33 (1.18-1.49)

1.86e-06

2

rs3733589 (SLC2A9; chr4:9985700)

GG

2005 (39.45)

4019 (35.62)

  

GA

2441 (48.02)

5393 (47.80)

0.91 (0.84-0.97)

7.93e-03

AA

637 (12.53)

1870 (16.58)

0.68 (0.62-0.76)

7.77e-13

3

rs3775948 (SLC2A9, Chr4:9993558)

GG

1886 (37.18)

3721 (33.07)

  

GC

2490 (49.08)

5386 (47.87)

0.91 (0.85-0.98)

1.34e-02

CC

697 (13.74)

2144 (19.06)

0.64 (0.58-0.71)

9.57e-18

4

rs1014290 (SLC2A9; chr4:10000237)

GG

1957 (38.49)

3900 (34.53)

  

GA

2464 (48.46)

5376 (47.60)

0.91 (0.85-0.98)

1.40e-02

AA

664 (13.06)

2019 (17.88)

0.64 (0.57-0.71)

1.56e-17

  1. OR odds ratio, 95% CI 95% confidence intervals